Ascendis Pharma Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	646.55	363.64	266.72	51.17	7.78	6.95
Revenue Growth (YoY)	97.46%	36.34%	421.20%	557.93%	11.87%	-48.02%
Cost of Revenue	85.34	44.26	44.4	12.14	3.52	-
Gross Profit	561.21	319.38	222.32	39.04	4.26	6.95
Selling, General & Admin	398.77	291.14	264.41	221.23	160.18	76.67
Research & Development	300.71	307	413.45	379.62	295.87	260.9
Operating Expenses	699.48	598.15	677.86	600.85	456.05	337.57
Operating Income	-138.28	-278.76	-455.54	-561.81	-451.79	-330.62
Interest Expense	-139.72	-65.5	-44.07	-30.68	-3.91	-1.92
Interest & Investment Income	75.05	14.36	16.86	7.43	0.69	1.81
Earnings From Equity Investments	10.41	-20.06	-18.4	-17.7	12.04	-9.52
Currency Exchange Gain (Loss)	-27.15	-27.15	12.35	40.43	59.03	-78.92
Other Non Operating Income (Expenses)	3.87	3.87	14.65	-15.48	-	-
Pretax Income	-223.33	-373.24	-474.14	-577.82	-383.94	-419.17
Income Tax Expense	9.61	4.84	7.3	5.38	-0.37	-0.22
Net Income	-232.94	-378.08	-481.45	-583.19	-383.58	-418.96
Net Income to Common	-232.94	-378.08	-481.45	-583.19	-383.58	-418.96
Shares Outstanding (Basic)	60	58	56	56	55	51
Shares Outstanding (Diluted)	60	58	56	56	55	51
Shares Change (YoY)	5.56%	2.85%	0.38%	2.37%	8.21%	8.84%
EPS (Basic)	-3.87	-6.53	-8.55	-10.40	-7.00	-8.28
EPS (Diluted)	-3.87	-6.53	-8.55	-10.40	-7.00	-8.28
Free Cash Flow	-112.15	-307.62	-469.8	-510.19	-441.35	-291.41
Free Cash Flow Per Share	-1.86	-5.31	-8.35	-9.10	-8.06	-5.76
Gross Margin	86.80%	87.83%	83.36%	76.28%	54.71%	100.00%
Operating Margin	-21.39%	-76.66%	-170.80%	-1097.85%	-5808.59%	-4755.07%
Profit Margin	-36.03%	-103.97%	-180.51%	-1139.63%	-4931.56%	-6025.53%
Free Cash Flow Margin	-17.35%	-84.60%	-176.14%	-996.97%	-5674.38%	-4191.11%
EBITDA	-133.71	-273.83	-448.99	-544.3	-436.85	-321.17
EBITDA Margin	-20.68%	-75.30%	-168.34%	-	-	-
D&A For EBITDA	4.57	4.94	6.55	17.51	14.95	9.45
EBIT	-138.28	-278.76	-455.54	-561.81	-451.79	-330.62
EBIT Margin	-21.39%	-76.66%	-170.80%	-	-	-

Updated Nov 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q